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REGULAR ARTICLE

ASXL1 impairs osteoclast formation by epigenetic regulation of NFATc1
Nidhi Rohatgi,1 Wei Zou,1 Patrick L. Collins,1 Jonathan R. Brestoff,1 Timothy H. Chen,2 Yousef Abu-Amer,2 and Steven L. Teitelbaum1,3
1

Department of Pathology and Immunology, 2Department of Orthopedic Surgery, and 3Division of Bone and Mineral Diseases, Department of Medicine, Washington University
School of Medicine, St. Louis, MO

Key Points

• ASXL1 deletion in
myeloid lineage cells
promotes osteoclast
differentiation resulting
in low bone mass.
• ASXL1 modulates
H3K27 methylation of
osteoclastogenic gene
promoters, including
NFATc1.

Additional sex comb-like 1 (ASXL1) mutations are commonly associated with myeloid
malignancies and are markers of aggressive disease. The fact that ASXL1 is necessary for
myeloid differentiation raises the possibility it also regulates osteoclasts. We ﬁnd deletion
of ASXL1 in myeloid cells results in bone loss with increased abundance of osteoclasts.
Because ASXL1 is an enhancer of trithorax and polycomb (ETP) protein, we asked if it
modulates osteoclast differentiation by maintaining balance between positive and
negative epigenetic regulators. In fact, loss of ASXL1 induces concordant loss of inhibitory
H3K27me3 with gain of H3K4me3 at key osteoclast differentiation genes, including nuclear
factor for activated T cells 1 (NFATc1) and itgb3. In the setting of ASXL1 deﬁciency, increased
NFATc1 binds to the Blimp1 (Prdm1) promoter thereby enhancing expression of this
pro-osteoclastogenic gene. The global reduction of K27 trimethylation in ASXL1-deﬁcient
osteoclasts is also attended by a 40-fold increase in expression of the histone demethylase
Jumonji domain‐containing 3 (Jmjd3). Jmjd3 knockdown in ASXL1-deﬁcient osteoclast
precursors increases H3K27me3 on the NFATc1 promoter and impairs osteoclast formation.
Thus, in addition to promoting myeloid malignancies, ASXL1 controls epigenetic reprogramming of osteoclasts to regulate bone resorption and mass.

Introduction
Osteoclast is the bone-resorbing, myeloid lineage polykaryon. In keeping with its myeloid ontogeny,
molecules which control myelopoiesis also regulate osteoclasts.
Osteoclast formation requires activation of RANK ligand (RANKL)/RANK signaling pathways including
NF-kB and MAPKs such as extracellular signal-regulated kinase and p38.1 These immediate signals
result in synthesis of c-Fos, which collaborates with the key osteoclastogenic transcription factor,
NFATc1, to autoactivate the latter’s promoter thereby inducing osteoclastogenesis.2 Although RANKL
induces epigenetic changes that contribute to osteoclast formation, the mechanisms underlying this
epigenetic remodeling in osteoclastogenesis still remain unclear.3
Additional sex comb-like (ASXL) genes encode enhancer of trithorax and polycomb (ETP) proteins,
which, by facilitating histone methylation or demethylation, repress or stimulate gene transcription in a
cell-specific context.4,5 Transcriptional repression by ASXL proteins is mediated by recruiting polycomb
receptor complex 2 (PRC2) to promoters, thereby increasing H3K27 methylation. Trimethylation of K27
results in gene inactivation, a process reversed by recruitment of a histone demethylase that removes
H3K27me3 methyl groups.6 These events also exist during osteoclastogenesis.7
An ASXL family gene, ASXL2, positively effects osteoclast formation as its deletion diminishes the
number of bone resorptive cells, resulting in osteopetrosis.8 Another member of the ASXL family, namely
ASXL1, is associated with and dictates prognosis of a number of myeloid malignancies such as
mastocytosis with associated myelodysplasia, which predisposes to osteoclast-dependent osteoporosis.9,10
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Like ASXL2, ASXL1 also recognizes PPARg, but whereas ASXL2
promotes adipogenesis, the process is arrested by ASXL1.11
Because ASXL1 suppresses the nuclear receptor (PPARg), whose
activity was presumed to promote physiological osteoclast formation, we postulated that specific deletion of ASXL1 in myeloid lineage
would induce the bone resorptive cell and diminish bone mass.12
Although mice lacking ASXL1, exclusively in myeloid lineage cells,
have low bone mass, their robust osteoclast formation is independent
of canonical RANKL- and PPARg-activated signals, including c-Fos
expression. Like its induction of hematopoietic malignancies,
however, the osteoclastogenic properties of ASXL1 deficiency
involve demethylation of a repressive histone mark, H3K27me3.
Consequently, the genes most affected by absence of ASXL1
are involved in osteoclast differentiation. A subset of these genes
gain K4 trimethylation, a mark of active chromatin, and were
enriched in NFAT-like motifs. One such gene is prdm1 (Blimp1),
the promoter of which exhibits increased binding to NFATc1 in
knockout (KO) cells. The reciprocal increase in H3K4me3 on
osteoclastic genes in ASXL1-deficient myeloid lineage cells may
also be because of activation of the histone demethylase Jumonji
domain‐containing 3 (Jmjd3), which specifically removes K27 methyl
groups from promoters. Thus, ASXL1 regulates osteoclast epigenome
and its inactivation promotes bone loss.

Methods
Animals
All animals were housed in the animal care unit of Washington University
School of Medicine, where they were maintained according to guidelines
of the Association for Assessment and Accreditation of Laboratory
Animal Care. All animal experimentation was approved by the Animal
Studies Committee of Washington University School of Medicine.

Generation of ASXL1-deficient mice
Asxl1tm1a(EUCOMM)Wtsi were purchased from European Conditional Mouse Consortium. For deletion of the LacZ-neomycinresistance cassette and for the generation of mice with LoxP-flanked
ASXL1 allele (ASXL1f/1), those transmitting 100% were bred to
FLPo (JAX mice 012930, C57BL/6 mice), which have transgenic
expression of an enhanced form of the recombinase FLP driven by
the GT(ROSA)26Sor promoter. ASXL1f/1 mice were intercrossed
to generate ASXL1f/f mice. ASXL1fl/fl mice generated were
subsequently crossed with LysM-Cre mice (Jackson Laboratory). To
fully delete ASXL1 using LysM-Cre, ASXL1fl/fl, LysMCre1/2 mice
were crossed again to obtain animals bearing 2 copies of the
LysM-Cre allele (ASXL1fl/fl LysMCre1/1 ). LysMCre1/1 and
ASXL1fl/fl littermate without Cre mice served as control.

Macrophage isolation and osteoclast culture
All in vitro experiments were performed at least 3 times. Primary
bone marrow macrophages (BMMs) were prepared as described13
with slight modification. Marrow was extracted from femora and
tibiae of 6- to 8-week-old mice with a minimum essential medium
(a-MEM) and cultured in a-MEM containing 10% inactivated fetal
bovine serum, 100 IU/mL penicillin, and 100 mg/mL streptomycin
(a-10 medium) with 1:10 of mMCSF producing cell line, CMG
14-12 condition media on petri-plastic dishes. Cells were incubated
at 37°C in 6% CO2 for 3 days and then washed with phosphatebuffered saline (PBS) and lifted with 13 trypsin/EDTA in PBS. A
total of 1.2 3 104 BMMs were cultured in 500 mL a-MEM containing
2468
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10% heat-inactivated fetal bovine serum with glutathione-S
transferase–RANKL and 30 ng/mL of mouse recombinant
macrophage colony-stimulating factor (M-CSF) in 48-well tissue
culture plates, some containing sterile bovine bone slices. Cells
were fixed and stained for tartrate-resistant acid phosphatase
(TRAP) activity after 5 days in culture, using a commercial kit (Sigma
387-A; Sigma-Aldrich, St. Louis, MO). The images were captured
using Nikon Eclipse E400 (Melville, NY) upright microscope.

Histone extraction, histone western blot
Histones were extracted by standard acid extraction protocol. Briefly,
cells were lysed in triton extraction buffer (PBS containing 0.5%
triton 3 100 [vol/vol]) on ice for 10 minutes. The cells were centrifuged
at 2000 rpm for 10 minutes followed by another wash with half the
volume of triton extraction buffer. Pellet was resuspended in 0.2N HCl.
Histones were acid extracted overnight at 4°C. The samples were
centrifuged and supernatant removed. Protein was determined using
Bradford assay.

Lentivirus infection
293-T cells were transfected with shJMJD3 together with a packaging
plasmid (pHR0 8.2 d R) and the envelope (pCMV-VSV-G) plasmid.
After 48 hours, medium containing lentiviruses was collected and
filtered. Macrophages obtained from 8- to 12-week-old male mice
were infected with virus for 24 hours in the presence of 1:10 CMG
and 10 mg/mL protamine (Sigma-Aldrich). Cells were selected
in the presence of CMG and 1 mg/mL puromycin (Calbiochem) for
3 days before use as osteoclast precursors.

Chromatin immunoprecipitation (ChIP) assay
For immunoprecipitation, 60 mL of magnetic protein A beads were
used. The beads were washed thrice with PBS containing 0.02%
tween 20. After the final wash, beads were resuspended with the
antibody overnight at 4°C. The next day, 1 to 2 million cells were plated
in tissue culture plates (6 RANKL). Formaldehyde was added directly
to cell culture media for 10 minutes at room temperature such that
the final concentration was 1%. Cross-linking was quenched by the
addition of glycine to a final concentration of 0.125 M. Cells were
washed 3 times with PBS, scraped off the plates in a small amount
of PBS, and centrifuged, and the pellet was washed with PBS
containing protease inhibitors (Complete, Roche). Cells were then
resuspended in 1 mL PBS, and protease inhibitors centrifuged
at 5000 rpm for 5 minutes at 4°C. The pellet was resuspended in
cold sonication buffer (50 mM tris(hydroxymethyl)aminomethane
[Tris]–HCl pH 8, 10 mM EDTA, 0.1% sodium dodecyl sulfate [SDS],
0.5% sodium deoxycholate and protease inhibitors) for 25 to
30 minutes on ice. Cells were aliquoted at 1 3 106 cells per mL
concentration and chromatin sheared using Bioruptor (6 cycles,
10 minutes at high speed per cycle). The samples were centrifuged
to pellet the cellular debris. Five percent of the cells were collected in a
separate tube to be used as input control. The supernatant was
divided equally between immunoprecipitation samples to include
isotype control. Sheared DNA was incubated with the beadantibody slurry. The next day, DNA-protein complexes were washed
in low salt buffer (SDS 0.1%, Triton X100 1%, EDTA 2 mM, TrisHCl pH 8.0 20 mM, NaCl 150 mM) followed by high salt buffer
(SDS 0.1%, Triton X100 1%, EDTA 2 mM, Tris-HCl pH 8.0 20 mM,
NaCl 500 mM), LiCl buffer (LiCl 0.25 M, nonidet P-40 1%,
deoxycholate 1%, EDTA 1 mM, Tris-HCl pH 8.0, 10 mM), and TrisEDTA buffer. DNA was eluted by adding 250 mL of elution buffer
9 OCTOBER 2018 x VOLUME 2, NUMBER 19

(SDS 1%, NaHCO3 0.1 M). Samples and inputs were de-crosslinked and cleaned for quantitative polymerase chain reaction (qPCR)
analysis.

Chromatin immunoprecipitation and DNA sequencing
(ChIP-seq) and analysis
ChIP or input DNA was used for indexed library preparation (Ilumina)
and then subjected to 50-bp single-end sequencing per manufacturer’s
protocol on Illumina HiSeq3000. Sequenced libraries were aligned to
the reference genome (mm10) using NovaAlign base settings. Peak
calling was performed using MACS2.0 for H3K4me3 ChIP-seq14 and
HOMER for H3K27me3 ChIP-seq,15 using paired inputs as peak
calling controls. For heat maps and quantification of reads over peaks,
genes, or promoter regions, reads per kilobase per million were
extracted using Deeptools.16 For log ratio (M) and average mean (A)
(MA) plot analysis, reads were then further quantile normalized using
the R package preprocessCore, prior to direct comparison. Direct
visualization of ChIP-seq tracks was accomplished using the University
of California, Santa Cruz Genome Browser.17

Statistics
Statistical significance was determined using multiple comparison
in a 1‐way or 2-way analysis of variance (ANOVA) test, or with unpaired
nonparametric Student t test when only 2 groups were present, using
GraphPad Prism v7 built‐in statistical analysis (GraphPad Software
Inc., La Jolla, CA). P , .05 was considered significant. All
quantitative reverse transcription–PCR and qPCR data were
expressed as mean from at least 3 independent biological experiments with at least 3 technical replicates.

Results
ASXL1 deletion in myeloid lineage cells promotes
osteoclastogenesis resulting in low bone mass
To assess the influence of osteoclast differentiation on ASXL1
expression, we cultured wild-type (WT) BMMs in the presence of
RANKL and M-CSF and temporally measured ASXL1 messenger RNA
(mRNA) and protein. Although the ETP gene was robustly expressed in
naı̈ve BMMs, abundance of its mRNA decreased approximately twothirds within 24 hours of RANKL/M-CSF exposure with progressive
decline as the osteoclast phenotype further matured (Figure 1A).
Because its expression declines with osteoclast differentiation, we
postulated ASXL1 may negatively impact formation of the bone
resorptive cell. We therefore conditionally deleted ASXL1 in
myeloid lineage cells by mating ASXL1flox/flox mice to those bearing
lysozyme M Cre (ASXL1cKO) leading to virtual arrested expression
of the targeted gene (Figure 1B; supplemental Figure 1A). The
conditionally deleted BMMs and their Cre- counterparts were
cultured in osteoclastogenic conditions with increasing amounts of
RANKL. After 5 days, the cells were stained for TRAP activity, and
the number of osteoclasts was counted. Regardless of the amount
of the osteoclastogenic cytokine, RANKL, ASXL1-deficient BMMs
generated more osteoclasts than controls (Figure 1C-D). The
abundance of ASXL1cKO osteoclasts was confirmed by substantially greater expression of differentiation marker mRNA and
protein, including NFATc1 (Figure 1E; supplemental Figure 1B). In
contrast to its generation, the resorptive capacity of individual
ASXL1cKO osteoclasts was intact as manifested by their ability to
organize their cytoskeleton to form actin rings and generate pits on
9 OCTOBER 2018 x VOLUME 2, NUMBER 19

bone (Figure 1F). In accordance, ASXL12/2 osteoclasts plated on
bovine bone slices mobilized significantly more carboxy-terminal
collagen (CTx), a marker of bone resorption than control cells
(Figure 1G). Interestingly, RANKL- and M-CSF-stimulated classical osteoclastogenic signaling events in ASXL1cKO BMMs were
unaltered indicating other pathways were inducing the robust
formation of the bone resorbing cell (supplemental Figure 1C-D).
Reflecting our in vitro observations, mCT analysis established a
33% loss of trabecular bone volume and a 14% reduction of bone
mineral density in ASXL1cKO mice (Figure 2A-B). The number of
osteoclasts were substantially enhanced in ASXL1 cKO femurs.
In consequence, histomorphometrically determined trabecular bone
volume was diminished (Figure 2C-D). Confirming robust osteoclastogenesis in ASXL1cKO mice, serum analysis of Trap5B, a hallmark of
osteoclast number, was elevated (Figure 2E). The decrease in bone
mass did not reflect altered osteoblastogenesis as both osteoblast
number per bone surface and P1NP serum levels remain unchanged
(supplemental Figure 2A-B).

ASXL1cKO osteoclast formation is not mediated by
c-Fos or increased osteoclast progenitors
Although controversial, we reported that ASXL2 deletion dampens
osteoclast formation by inactivating PPARg.8 We therefore asked if
absence of ASXL1 induced osteoclast differentiation in a reciprocal
manner, namely, by stimulating the nuclear receptor, PPARg. To
determine if such is the case, we quantified the essential PPARg
osteoclastogenic target, c-Fos, which was modified by ASXL2.8
Confirming the osteoclastogenic effect of ASXL1 deletion is likely
not mediated by PPARg, c-Fos expression was unaltered in
RANKL/M-CSF–treated ASXL1cKO BMMs (supplemental Figure 2C).
Given the role of ASXL1 in the hematopoietic compartment,18 we then
asked if ASXL1 deletion with LysMcre may regulate hematopoiesis and osteoclast development. We found that the mice with
ASXL1-deficient myeloid cells had normal bone marrow cellularity
(supplemental Figure 3A) and exhibited no splenomegaly (supplemental Figure 3B). Fluorescence-activated cell sorter analysis of
marrow also revealed that conditional myeloid deletion of ASXL1
did not alter frequencies or numbers of lineage negative, sca1 positive,
c-kit negative (LSK), common myeloid progenitor, granulocyte/
macrophage progenitor, megakaryocyte/erythroid progenitor,
(supplemental Figure 3C) or RANK1 osteoclast progenitor cells
(supplemental Figure 3D-E) in bone marrow. In addition, 5-bromo-29deoxyuridine incorporation established that proliferation of BMMs
and preosteoclast was unaltered between the 2 genotypes (supplemental Figure 4A-B). To evaluate for possible hematopoietic defects,
bone marrow cells were isolated from femurs of ASXL1flox/flox and
ASXL1cKO female mice (supplemental Figure 5A). Consistent with
the progenitor data, we also found that frequencies and numbers of
macrophages, Ly6Chi monocytes, Ly6Clo monocytes, neutrophils,
CD191 B cells, bulk CD31 T cells, CD41 T cells, CD81 T cells, and
CD42CD82 T cells were unaltered in ASXL1cKO mice (supplemental Figure 5B). Eosinophil frequencies and numbers (supplemental Figure 5B) were, however, slightly decreased in ASXL1cKO
bone marrow (P , .05). Erythrocyte frequencies and numbers
(supplemental Figure 5C-D) were also similar in ASXL1flox/flox and
ASXL1cKO mice. Thus, conditional deletion of ASXL1 in myeloid
lineage cells results in relatively specific hematopoietic alterations
affecting osteoclasts and eosinophils but no other cell types, at
least in mice #12 weeks of age.
ASXL1 IMPACTS H3K27me3 EPIGENOME OF OSTEOCLASTS
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Figure 1. ASXL1 deletion in myeloid lineage cells promotes osteoclastogenesis. (A) Six- to 8-week-old WT BMMs were exposed to M-CSF and RANKL (50 ng/mL)
for 5 days. ASXL1 mRNA expression was determined by qPCR. One-way ANOVA was used to determine statistical differences. Data are represented as 1 standard deviation (SD).
***P , .001 relative to BMM control. (B) ASXL1flox/flox and ASXL1cKO BMMs were cultured with M-CSF 1 RANKL (50 ng/mL) for 5 days. ASXL1 protein was determined by
immunoblot. (C) Representative image showing ASXL1flox/flox and ASXL1cKO BMMs cultured in M-CSF and RANKL (25 ng/mL and 100 ng/mL) for 5 days, after which cells were stained
for TRAP activity. The images were captured using Nikon Eclipse E400 upright microscope. Scale bar represents 400 mm. (D) TRAP positive osteoclasts were then counted. Unpaired
nonparametric Student t test was used to determine statistical differences. Error bars represent 1 SD; *P , .05, **P , .01 in comparison with their respective controls. (E) ASXL1flox/flox
and ASXL1cKO BMMs were cultured with M-CSF and RANKL (50 ng/mL) for 4 days. Total cell lysate was collected with time. Osteoclast differentiation proteins were determined by
immunoblot. (F) ASXL1flox/flox and ASXL1cKO BMMs were cultured with M-CSF and RANKL (100 ng/mL) on bovine bone slices. After 5 days, the cells were stained with Alexa-Fluor-546phallodin to visualize the actin rings (top). The images were captured on the green channel of Nikon Eclipse E400 upright microscope. Following removal of the transduced osteoclasts,
resorption pits were visualized by wheat germ agglutinin-lectin staining (bottom). Scale bar represents 100 mm. (G) ASXL1flox/flox and ASXL1cKO BMMs were cultured with M-CSF and
RANKL (100 ng/mL) for 6 days on bovine bone slices. Conditioned medium was assayed for CTx (6 bone slices were used for both genotypes). Error bars represent 1 SD; **P , .01.
All experiments were conducted at least 3 times.
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Figure 2. ASXL1cKO mice have low bone mass. (A-B) Femurs of 13-week-old male ASXL1
mCT analysis (n 5 5 in each group). Scale bar represents 100 mm. (C-D) Femurs of ASXL1
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Scale bar represents 1 mm. Histomorphometric analysis of osteoclast number (OcN) per bone surface (BS) and ratio of trabecular bone volume (BV) to total marrow space
(total volume [TV]) of ASXL1flox/flox and ASXL1cKO mice (n 5 5 in each group) quantified using BioQuant software. (E) Serum analysis for TRAP5B in ASXL1flox/flox and
ASXL1cKO 12-week-old male mice (n 5 7 mice in each group). Unpaired nonparametric Student t test was used for statistical analysis. Error bars represent 1 SD; *P , .05,
**P , .01, ***P , .001. BV/TV, bone volume fraction of marrow; Conn-Dens, connectivity density, normed by TV; ns, not significant; TbN, trabecular number; TbSp, trabecular
separation; TbTh, trabecular thickness; vBMD, volumetric bone mineral density.

ASXL1 deficiency alters H3K27me3 methylation
of gene promoters
ASXL1 depletion leads to a marked reduction in genome-wide
H3K27me3 in hematopoietic cells altering target gene expression.18 We therefore asked if K27 trimethylation was altered in
osteoclast lineage ASXL1cKO cells such that ASXL1 deletion may
have activated relevant genes. Like myeloid malignancies, bulk
H3K27 methylation in fact was diminished in ASXL1-deficient
preosteoclasts (Figure 3A). To identify genes regulated by these
events in osteoclasts, we performed ChIP-seq. As a functional
readout of ASXL1 activity, we used H3K27me3 and H3K4me3
antibodies to measure relative levels of transcriptional repression
and promoter activation, respectively, in ASXL1flox/flox and ASXL1cKO
osteoclasts. As observed in the immunoblot, ChIP-seq data also
revealed a global reduction in K27 trimethylation in the KO osteoclast.
Of 25 321 H3K27me3 peaks found in either genotype, WT had
fivefold more unique peaks than KO cells (Figure 3B, left panel). In
addition, analysis of H3K27me3 levels across all genes (Figure 3B,
right panel shows chromosome 1) indicated a global trend for loss
9 OCTOBER 2018 x VOLUME 2, NUMBER 19

of total H3K27me3. Gene-specific loss of H3K27me3 was
supported by analyzing read coverage over all genomic features,
which revealed a shift from promoter reads in WT cells to distal
intragenic reads in the KO cells (Figure 3C).
Given chromosome-wide depletion of H3K27me3, we asked if
genes most affected by ASXL1 loss were specific to osteoclast
development. A total of 663 genes in KO osteoclast exhibited
significant loss of K27 methylation (criteria used was greater
than twofold change between the 2 groups). Of these, Gene Set
Enrichment Analysis revealed significant enrichment of osteoclast differentiation pathway as well as transcriptional regulation
(Figure 3D; supplemental Figure 6). Thus, although KO of
ASXL1 broadly impacted the H3K27me3 epigenome of osteoclasts, we could identify subsets of genes that may be specifically
regulated by ASXL1.
As loss of ASXL1 resulted in promoter-specific depletion of
H3K27me3, we analyzed for concordant loss of H3K27me3 with
gain of the promoter histone modification H3K4me3. MA plots
document K27 methylation of the key osteoclastic genes, NFATc1,
ASXL1 IMPACTS H3K27me3 EPIGENOME OF OSTEOCLASTS
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Figure 4. Increased pro-osteoclastogenic transcription factors in ASXL1-deficient osteoclasts. (A) ASXL1flox/flox and ASXL1cKO BMMs were exposed to M-CSF and
RANKL (50 ng/mL) for 2 days. H3K27me3 binding to NFATc1 response element in the NFATc1 promoter was determined by ChIP assay. Immunoglobulin G (IgG) served as
a control. (B) ASXL1flox/flox and ASXL1cKO BMMs were cultured in M-CSF and RANKL (50 ng/mL) for 1 day. PRC proteins were determined by immunoblot. Actin served as
loading control. (C) ASXL1flox/flox and ASXL1cKO BMMs were cultured in the presence of M-CSF and RANKL (50 ng/mL). RNA was harvested on days 1 and 2 of RANKL
stimulation, and Blimp1 mRNA abundance was determined by qPCR. (D) ASXL1flox/flox and ASXL1cKO BMMs were exposed to M-CSF and RANKL (50 ng/mL) for 2 days.
H3K27me3 binding to Blimp1 promoter was determined by ChIP assay. IgG served as control. (E) ASXL1flox/flox and ASXL1cKO BMMs were exposed to M-CSF and RANKL
(50 ng/mL) for 2 days. NFATc1 binding to Blimp1 promoter was determined by ChIP assay. IgG served as control. n 5 3 independent experiments from 10- to 12-week-old
male mice. Two-way ANOVA was used for statistical analysis. Error bars represent 1 standard error of the mean; **P , .01, ***P , .001.

itgb3, Mmp9, and Mmp14 to have increased K27 methylation in the
ASXL1flox/flox in comparison with KO (Figure 3E, top). On the other
hand, alterations of K4 methylation, an indicator of active
chromatin, were much less dramatic on some of these gene
promoters (Figure 3E, bottom). Importantly, K27 methylation
on promoters upstream of TSS of specific genes such as
NFATc1, itgb3, and Mmp14 visualized using University of
California, Santa Cruz Genome Browser was decreased (Figure
3F). These observations raised the possibility that depletion of
ASXL1 de-represses transcription factors that drive the formation of new H3K4me3 positive promoters. To identify these
potential regulatory pathways, we performed a motif enrichment
analysis of novel H3K4me3 peaks specific to the ASXL1cKO cells.
Utilizing de novo motif prediction, and a highly stringent statistical cut
off (P , 1e-50), we identified enrichment of NFAT-like motifs in the KO

promoters (P value 51e-52) (Figure 3G; supplemental Tables 1
and 2). ASXL1cKO osteoclast lineage cells exhibit specific loss of
H3K27me3 with gain of H3K4me3 at the NFATc1 promoter, along
with genome-wide enrichment of NFAT motifs in the novel ASXL1KO promoters.

Increased pro-osteoclastogenic transcription factors
in ASXL1-deficient osteoclasts
Additional ChIP-qPCR using H3K27me3 antibody validated the
ChIP-seq observation that H3K27me3 enrichment of the NFATc1
promoter was markedly reduced in ASXL1cKO osteoclasts (Figure 4A).
This observation, taken with NFAT enrichment on actively transcribing
genes in KO cells, indicated the enhanced osteoclast formation
attending cell-autonomous ASXL1 deficiency represents demethylation of NFATc1-residing H3K27me3.

Figure 3. ASXL1 deficiency alters H3K27me3 methylation on gene promoters. (A) ASXL1flox/flox and ASXL1cKO BMMs from 12-week-old male mice were cultured with
M-CSF and 50 ng/mL RANKL for 2 days. Representative immunoblot of bulk histone methylation for H3K27me3 on acid extracted histones. Total H3 was used as a loading control
(n 5 3 independent experiments). (B) ASXL1flox/flox (WT) and ASXL1cKO (KO) osteoclast were chromatin immunoprecipitated using H3K27me3 or H3K4me3 antibody followed by
DNA sequencing. Model based analysis of ChIP-seq data (MACS2) for H3K27me3 methylation. Left: Venn diagram made with http://jolars.co/eulerr/. Right: Heat map for
H3K27me3 on chr1 in ASXL1flox/flox and ASXL1cKO osteoclast (13 kb of transcription start site [TSS]). (C) Characterization of H3K27me3 binding sites in various genomic regions
in ASXL1flox/flox and ASXL1cKO osteoclasts. (D) Gene sets uniquely enriched in KO mice with H3K27me3 loss using Kyoto Encyclopedia of Genes and Genomes pathway analysis.
(E) MA plots for H3K27me3 (up) and H3K4me3 (down) to visualize genes (data points) that are being identified as differentially bound (red). Osteoclast relevant genes identified in
blue. (F) H3K27me3 peaks at individual loci (highlighted blue bar), NFATc1, itgb3, and Mmp14; WT (ASXL1flox/flox) and KO (ASXL1cKO). (G) Motif enrichment analysis of novel
H3K4me3 binding sites in ASXL1cKO osteoclasts.
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ASXL1 regulates transcription by interacting with PRC2, which
includes EZH2, Suz12, and EED.19 Thus, ASXL1 deficiency may
alter the PRC2 complex proteins, thereby attenuating H3K27me3
methylation. For example, robust osteoclastogenesis attending
ASXL1 deficiency may represent an abundance of EZH2, which
delivers methylated H3K27 to the promoter of Irf8, thereby silencing
its osteoclast-inhibiting properties.20 To explore this possibility, we
measured PRC2 proteins in ASXL1cKO macrophages and osteoclastic
cells. Despite decreased H3K27me3 methylation in ASXL1cKO
osteoclasts, expression of PRC2 core members in mutant BMMs
was unchanged, even as they underwent osteoclast differentiation (Figure 4B). Blimp1 (encoded by Prdm121), an established
positive regulator of osteoclastogenesis, and a transcriptional
repressor of antiosteoclastogenic genes, increased in ASXL1-KO
osteoclasts (Figure 4C). In contrast to NFATc1, however, H3K27me3
on Blimp1 promoter was not significantly different between the control
and KO osteoclasts (Figure 4D), indicating absence of ASXL1
likely did not exert its Blimp1 inductive effect directly by regulating
histone methylation. Consistent with previous reports that NFATc1
regulates Blimp1 expression,17 ASXL1-deletion markedly enhanced NFATc1 occupancy on the Blimp1 promoter (Figure 4E).

Loss of H3K27me3 in ASXL1-deficient osteoclasts is
mediated by JMJD3
The loss of K27 methylation in ASXL1cKO osteoclasts could likely
be because of removal of methyl groups from the lysine residues
on histone H3, by a demethylase specific to K27 trimethylation,22
Jmjd3. The effects of ASXL1 loss on H3K27me3 occupancy
raised the possibility of whether K27 methylation on the Jmjd3
promoter was also altered. However, H3K27me3 on the Jmjd3
promoter near the TSS was unchanged. Although its significance is enigmatic, K27 methylation of promoter elements
further upstream was decreased (Figure 5A). In addition, we
found expression of Jmjd3 increased 40-fold in ASXL1-deficient
osteoclasts (Figure 5B). Fortifying its relevance to ASXL1-deficient
osteoclastogenesis, Jmjd3 knockdown in ASXL1cKO BMMs (supplemental Figure 7) also restored H3K27me3 methylation on
osteoclastogenic gene promoters, including NFATc1 and Blimp1
(Figure 5C-D). Consequently, Jmjd3 knockdown specifically in KO
osteoclasts also prevented expression of both NFATc1 and Blimp1
(Figure 5E). This decrease in pro-osteoclastogenic genes with Jmjd3
knockdown further arrested osteoclast formation (Figure 5F). Thus,
ASXL1 negatively regulates osteoclastogenesis by altering histone
methylation on osteoclast gene promoters (Figure 6).

Discussion
ASXL1 mutations in patients with systemic mastocytosis and
associated clonal hematologic non–mast-cell disease induce
osteoporosis.10 However, the relationship between osteoclasts
and myeloid leukemias, particularly those with inactivating ASXL1
mutations, which profoundly compromise survival, is enigmatic.9
ASXL1 is indispensable to myeloid differentiation, and we find mice
bearing ASXL1-deficient myeloid precursors form more osteoclasts
than their littermate controls resulting in low bone mass. Surprisingly, the enhanced osteoclastogenesis of ASXL1cKO mice is not
characterized by activation of IkBa, extracellular signal-regulated
kinase, and other MAPKs, which typically attend RANKL and
M-CSF signaling. Although the changed osteoclast number may
also reflect precursor abundance or apoptosis of the mature
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polykaryon, we found marrow cell abundance is unaltered, with no
changes in the hematopoietic progenitor population. This is consistent
with previous literature that establishes osteoclasts are not required
for hematopoietic stem cell maintenance and mobilization.23
Like ASXL2, ASXL1 recognizes PPARg, but in contrast to the
negative consequences of ASXL2 deletion, lack of ASXL1 promotes
adipogenesis, at least in vitro.8,11 In addition to its effects on lipid
and insulin homeostasis, PPARg is postulated to be an essential
component of the osteoclastogenic process, and we demonstrated
that ASXL2 2 /2 mice have a paucity of osteoclasts and are
osteopetrotic.8,12 We established, however, that although PPARg
mediates thiazolidinedione-stimulated osteoclast formation, its
absence does not alter osteoclast abundance in physiological
and pathological circumstances.24 This observation challenged
our conclusion that the osteopetrosis of ASXL22/2 mice reflects
inactivation of PPARg and prompted us to explore alternative
signaling pathways whereby ASXL1 deletion stimulates formation
of the bone resorptive cell. The present study also indicates that
osteoclastogenic effects of ASXL1 deletion are not indicative of
PPARg activity. This conclusion rests on the lack of effect of ASXL1
deletion on expression of c-Fos, which is the directly induced key
mediator whereby PPARg promotes osteoclast formation in response to thiazolidinediones.12 Despite absence of c-Fos induction, typically a central event inducing NFATc1, expression of the
latter is enhanced in ASXL12/2 osteoclast lineage cells.
The unaltered expression or activation of classical osteoclastogenic
signaling molecules, including MAPKs, IkBa, and c-Fos, suggests that
the increased osteoclast differentiation resulting from ASXL1 deletion
reflects an alternative mechanism such as epigenetic regulation. This
conclusion is in keeping with the established capacity of ASXL1 to
enhance or suppress gene expression by altering histone methylation
in a gene- and cell-specific manner. In the absence of ASXL1, genes
are demethylated, and its repressive activity arrested. In fact,
suppression of PRC2 recruitment is a likely means by which ASXL1
mutations contribute to the pathogenesis of aggressive myeloid
malignancies.18 This suggests that epigenetic mechanisms may
also mediate osteoclastogenic effects of associated with ASXL1
deletion. We found a reduction in bulk H3K27 trimethylation in
ASXL1-deficent osteoclast lineage cells. This observation prompted us to determine expression of candidate genes that regulate
osteoclast formation by modifying histone methylation. EZH2 is a
key component of PRC2, which promotes osteoclast formation by
suppressing the inhibitor Irf8.20 Thus, we expected enhanced EZH2 in
ASXL1cKO osteoclasts but observed a diminution, suggesting PRC2
members are not central to epigenetic modifications in the conditionally
deleted animals promoting their abundance of osteoclasts.
Blimp 1 is a transcriptional repressor that promotes osteoclast
differentiation by reducing inhibitors such as Irf8 and Mafb.21 Because
it is transduced by NFATc1, we asked if Blimp1 is a possible mediator
of ASXL1 deficiency–induced osteoclast formation. The substantial
increase in Blimp1 mRNA in ASXL1-deficient osteoclasts, in the
absence of altered H3K27me3 methylation, indicates that Blimp1
(Prdm1) transactivation is directly induced by abundant, epigenetically stimulated NFATc1 binding to its promoter.
Involvement of H3K27me3 demethylase provides another likely
explanation for increased Blimp1 in ASXL1-deficient osteoclasts.
Jmjd3 is an H3K27me3 demethylase that inhibits somatic cell
reprogramming by enhancing P16INK4a 25 and may undergo a
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Figure 5. Loss of H3K27me3 in ASXL1-deficient osteoclasts is mediated by Jmjd3. (A) H3K27me3 peaks at individual loci (highlighted blue bar) on Jmjd3
promoter; WT (ASXL1flox/flox) and KO (ASXL1cKO). (B) ASXL1flox/flox and ASXL1cKO BMMs were cultured in the presence of M-CSF and RANKL (25 ng/mL). RNA was
harvested on days 1 and 2 of RANKL stimulation, and histone H3 Lys 27 (H3K27) demethylase Jmjd3 mRNA abundance was determined by qPCR. Unpaired
nonparametric Student t test was used for statistical analysis. Error bars represent 1 SD; **P , .01, ***P , .001. (C-D) ASXL1cKO BMMs, transduced with scr or Jmjd3
short hairpin RNA (shRNA), were exposed to M-CSF and RANKL (25 ng/mL) for 2 days. H3K27me3 binding to NFATc1 promoter (C) and Blimp1 promoter (D) was
determined by ChIP assay. IgG served as control. n 5 2 independent experiments from 10- to 12-week-old male mice. Two-way ANOVA was used for statistical analysis.
Error bars represent 1 standard error of the mean; ***P , .001. (E) ASXL1 cKO BMMs, transduced with scr or Jmjd3 shRNA, were exposed to M-CSF and 1 RANKL
for 3 days. Expression of osteoclast differentiation proteins NFATc1 and b3 integrin was determined by immunoblot (left) and Blimp1 by qPCR (right). n 5 3
independent experiments from 8-week-old male mice. One-way ANOVA was used for statistical analysis. Error bars represent 1 SD; *P , .05, **P , .01. (F)
ASXL1cKO BMMs, transduced with scr or shRNA for Jmjd3, were exposed to M-CSF and 1 RANKL for 5 days and stained for TRAP activity. Images were captured
on Nikon Eclipse E400. Scale bar represents 400 mm.

PRC2-mediated epigenetic switch.26 Although regulation of
JMJD3 is enigmatic, its capacity to demethylate H3K27me3 on
the NFATc1 promoter and thus stimulate osteoclast formation is
established.7 We find Jmjd3 expression markedly enhanced in
ASXL1cKO cells, and its knockdown arrests their increased osteoclastogenesis by promoting H3K27me3 methylation on bone resorptive
genes. The size of the ASXL1 gene (;6 kb) compromised
9 OCTOBER 2018 x VOLUME 2, NUMBER 19

overexpressing ASXL1 in KO cells and directly assessing its role
in regulating Jmjd3, which will be a future goal. Nonetheless, our
study establishes that ASXL1 regulates osteoclast epigenome
via expression of Jmjd3, which demethylates H3K27m3 on the
NFATc1 promoter increasing its sensitivity to RANKL. Enhanced
NFATc1 in turn binds to and activates pro-osteoclastogenic
genes such as Blimp1.
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Figure 6. Schematic representation for role of ASXL1 in regulating osteoclastogenesis. ASXL1 binds to PRC2 proteins to methylate promoters of key osteoclast
differentiation genes such as NFATc1 and regulate their expression (left). Absence of ASXL1 prevents PRC2-mediated histone methylation (right). Jmjd3, specific demethylase
for H3K27me3 in turn removes K27 methyl groups from promoters such as NFATc1, resulting in increased osteoclastogenesis.

Although the relationship between myeloid linage cells and
osteoclasts is established, these findings show that mutations
promoting hematopoietic malignancies may also directly modulate
osteoclast formation. Thus, the osteoclastogenesis of ASXL1
deficiency does not involve classical RANKL- or M-CSF-stimulated
molecules such as MAPKs and c-Fos but activation of NFATC1 by
reversal of suppressive histone methylation. Epigenetic modification of myeloid lineage genes is therefore central to skeletal
homeostasis and may participate in malignancy associated bone
loss.
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